Patient characteristics
| Patient/disease characteristics . | Blinatumomab treatments . | Outcomes . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at blinatumomab administration, y/sex . | Disease status . | Pre-CNS status . | Pre-MRD, % . | Lymphocyte count pre-blinatumomab (×109/mL) . | Cycles, n . | CRS . | Neurotoxicity . | Post-MRD, % . | HSCT conditioning . | Donor source . | Status . |
| 0.75/M | CR2 | CNS 1 | 0.1 | 0.94 | 1 | No | No | <0.005 | FBT | MUD | CR |
| 0.75/F | CR2 | CNS 3 | 0.6 | 0.22 | 1 | No | No | <0.005 | FTT | MSD | CR |
| 0.5/M | CR2 | CNS 1 | 1 | 0.55 | 1 | Grade 1 | No | <0.005 | FTT + ATG | MMUD | CR |
| 0.41/F | CR2 | CNS 1 | 1 | N/A | 1 | No | No | <0.005 | FTT | MSD | Relapse→died* |
| 0.5/M | Primary refractory | CNS 1 | 9 | 0.28 | 1 | No | No | 0.06 | FTT + ATG | MUD | CR |
| 0.5/M | CR2 | CNS 1 | 0.3 | 0.35 | 1 | No | No | 0.05 | N/A | Relapse→CR† | |
| 0.5/F | CR1 | CNS 1 | 0.06 | 0.41 | 1 | Grade 2 | Yes | <0.005 | FTT + ATG | MMSD | CR |
| 0.2/F | CR1 | CNS 1 | 0.06 | 2.43 | 1 | No | No | <0.005 | FTT | MSD | Relapse‡ |
| 0.2/M | First relapse | CNS 3 | 40 | N/A | 1 | Grade 1 | No | <0.005 | FTT + ATG | MUD | Died§ |
| 2.9/M | CR2 | CNS 1 | 0.01 | 0.95 | 2 | No | No | <0.005¶ | CY/TBI/Alem | MSD | CR |
| 0.2/F | Primary refractory | CNS 1 | 9 | N/A | 2 | No | No | <0.005¶ | FTT/ATG | MUD | Relapse→CR|| |
| Patient/disease characteristics . | Blinatumomab treatments . | Outcomes . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at blinatumomab administration, y/sex . | Disease status . | Pre-CNS status . | Pre-MRD, % . | Lymphocyte count pre-blinatumomab (×109/mL) . | Cycles, n . | CRS . | Neurotoxicity . | Post-MRD, % . | HSCT conditioning . | Donor source . | Status . |
| 0.75/M | CR2 | CNS 1 | 0.1 | 0.94 | 1 | No | No | <0.005 | FBT | MUD | CR |
| 0.75/F | CR2 | CNS 3 | 0.6 | 0.22 | 1 | No | No | <0.005 | FTT | MSD | CR |
| 0.5/M | CR2 | CNS 1 | 1 | 0.55 | 1 | Grade 1 | No | <0.005 | FTT + ATG | MMUD | CR |
| 0.41/F | CR2 | CNS 1 | 1 | N/A | 1 | No | No | <0.005 | FTT | MSD | Relapse→died* |
| 0.5/M | Primary refractory | CNS 1 | 9 | 0.28 | 1 | No | No | 0.06 | FTT + ATG | MUD | CR |
| 0.5/M | CR2 | CNS 1 | 0.3 | 0.35 | 1 | No | No | 0.05 | N/A | Relapse→CR† | |
| 0.5/F | CR1 | CNS 1 | 0.06 | 0.41 | 1 | Grade 2 | Yes | <0.005 | FTT + ATG | MMSD | CR |
| 0.2/F | CR1 | CNS 1 | 0.06 | 2.43 | 1 | No | No | <0.005 | FTT | MSD | Relapse‡ |
| 0.2/M | First relapse | CNS 3 | 40 | N/A | 1 | Grade 1 | No | <0.005 | FTT + ATG | MUD | Died§ |
| 2.9/M | CR2 | CNS 1 | 0.01 | 0.95 | 2 | No | No | <0.005¶ | CY/TBI/Alem | MSD | CR |
| 0.2/F | Primary refractory | CNS 1 | 9 | N/A | 2 | No | No | <0.005¶ | FTT/ATG | MUD | Relapse→CR|| |
Alem, alemtuzumab; ATG, anti-thymocyte globulin; CNS, central nervous system; CRS, cytokine release syndrome; CY, cyclophosphamide; F, female; FBT, fludarabine, busulfan, thiotepa; FTT, fludarabine, treosulfan, thiotepa; M, male; MMSD, mismatched sibling donor; MSD, matched sibling donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; N/A, not available; TBI, total body irradiation.
Relapse with acute myeloid leukemia posttransplant.
B-ALL relapse posttransplant, remission following CAR T-cell therapy.
B-ALL relapse posttransplant, planned CAR T-cell therapy.
Died from posttransplant pneumonitis.
Results after 2 cycles.
B-ALL relapse posttransplant, remission following CAR T-cell therapy.